Acetium

Satya Abadi Pharma to distribute Acetium® lozenge in Indonesia

Biohit Oyj and Satya Abadi Pharma have signed an agreement for the distribution of the Acetium lozenge in Indonesia.

 

Acetium® lozenges contain L-cysteine, a natural amino acid that binds carcinogenic acetaldehyde dissolved in saliva from cigarette smoke.1 The lozenge also contains xylitol to reduce the production of acetaldehyde by bacteria in the mouth and improve overall oral hygiene. Normal saliva does not contain acetaldehyde.1 Acetaldehyde is a carcinogen2 and one of the harmful substances in tobacco smoke. The Acetium® lozenge removes up to 90 % of smoke-derived acetaldehyde in saliva.

The effectiveness of Acetium® lozenge in smoking intervention has been evaluated in two clinical trials.3- 4 If a lozenge is sucked every time a cigarette is smoked, eventually the taste of cigarettes changes and the pleasure of smoking decreases making it is easier to quit. For more info, please visit www.acetium.com

Acetium® lozenges is produced by Biohit Oyj, a globally operating Finnish biotechnology company. Biohit’s mission is "Innovating for Health”, they produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the United Kingdom. Biohit’s series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small cap/Healthcare. More information about Biohit can be found in www.biohit.fi

 

CEO Semi Korpela, Biohit Oyj: “The Acetium® lozenge for smoking cessation is an innovation developed and manufactured in Finland. It contains L-cysteine that binds carsinogen acetaldehyde. The Acetium® lozenge removes up to 90 % of smoke-derived acetaldehyde in saliva. Free from nicotine and side effects, Acetium® offers a safe method for those trying to quit smoking.”

 

CEO Agus Suwarno, PT. Satya Abadi Pharma:”We are very honored to represent Biohit and distribute Acetium® lozenge in Indonesia. As a marketing and distribution company in pharmaceutical and medical equipment who have a wide and diverse distribution channel all over Indonesia, we believe that the product supports our portfolio and will have a growing demand in Indonesia. Smoking is an important public health problem in Indonesia. There are up to 60 million active smokers in Indonesia. Every year, more than two hundred thousand people are killed by tobacco-caused disease. Most of the smokers are afraid of the dangers of cancer caused by cigarette and try to quit smoking. Acetium® lozenge is the product they need."

 

 

  1. Salaspuro VJ et al. Eliminating carcinogenic acetaldehyde by cysteine from saliva during smoking. Cancer Epid Biomark Prev 2006;15:146-149.
  2. Secretan B et al. WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens- Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009;10:1033-1034.
  3. Syrjänen K et al. Elimination of cigarette smoke-derived acetaldehyde in saliva by slow-release L-cysteine lozenge is an effective new method to assist smoking cessation. A randomised, double-blind, placebo-controlled intervention. Anticancer Res.  2016;36:2297-2306.

4. Syrjänen K et al. Slow-release L-cysteine (Acetium) lozenge is an effective new method in smoking cessation. A randomized, double-blind, placebo-controlled intervention. Anticancer Res 2017;37:3639-3648.

 

 

 

 

Search